Skip to main content
Fig. 1 | Infectious Agents and Cancer

Fig. 1

From: CD147 and cyclophilin A: a promising potential targeted therapy for COVID-19 and associated cancer progression and chemo-resistance

Fig. 1

The illustration shows the role of CD147 as a SARS-CoV-2 entry receptor. SARS-CoV-2 can stimulate intracellular signaling pathways of CD147 in host cells (cancer cells). Also, COVID-19 infection-induced hypoxia can lead to HIF-1α activation and transcriptional activity to increase the expression of CD147 and CyPA. All of these can potentially contribute to cancer progression and chemo-resistance

Back to article page

Infectious Agents and Cancer

ISSN: 1750-9378

Contact us